[go: up one dir, main page]

MX2017014191A - Metodos de tratamiento de una enfermedad neurodegenerativa. - Google Patents

Metodos de tratamiento de una enfermedad neurodegenerativa.

Info

Publication number
MX2017014191A
MX2017014191A MX2017014191A MX2017014191A MX2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A MX 2017014191 A MX2017014191 A MX 2017014191A
Authority
MX
Mexico
Prior art keywords
neurodegenerative disease
treating
methods
phenylsulfonyl
piperazinyl
Prior art date
Application number
MX2017014191A
Other languages
English (en)
Inventor
M Lewis Bryan
Tim Friedhoff Lawrence
Clement PISCITELLI Stephen
Kishnani Kunal
Ramaswamy Shankar
Original Assignee
Axovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axovant Sciences Gmbh filed Critical Axovant Sciences Gmbh
Publication of MX2017014191A publication Critical patent/MX2017014191A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a nuevos usos de antagonistas del receptor 5-HT6, específicamente dosis altas de 3-fenilsulfonil-8-piperazinil-lil-quinolina, y a la combinación de antagonistas del receptor 5-HT6, específicamente 3-fenilsulfonil-8-piperazinil-lil-quinolina, con un inhibidor de acetilcolinesterasa para el tratamiento de una enfermedad neurodegenerativa.
MX2017014191A 2015-05-07 2016-05-06 Metodos de tratamiento de una enfermedad neurodegenerativa. MX2017014191A (es)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201562158422P 2015-05-07 2015-05-07
US201562162193P 2015-05-15 2015-05-15
US201562162060P 2015-05-15 2015-05-15
US201562162068P 2015-05-15 2015-05-15
US201562162138P 2015-05-15 2015-05-15
US201562165034P 2015-05-21 2015-05-21
US201562168246P 2015-05-29 2015-05-29
US201562167986P 2015-05-29 2015-05-29
US201562169414P 2015-06-01 2015-06-01
US201562182225P 2015-06-19 2015-06-19
US201562189089P 2015-07-06 2015-07-06
US201562191189P 2015-07-10 2015-07-10
US201562201494P 2015-08-05 2015-08-05
US201562201513P 2015-08-05 2015-08-05
US201562239530P 2015-10-09 2015-10-09
US201562251534P 2015-11-05 2015-11-05
US201562256349P 2015-11-17 2015-11-17
US201562261115P 2015-11-30 2015-11-30
US201662289162P 2016-01-29 2016-01-29
US201662289643P 2016-02-01 2016-02-01
PCT/US2016/031359 WO2016179566A1 (en) 2015-05-07 2016-05-06 Methods of treating a neurodegenerative disease

Publications (1)

Publication Number Publication Date
MX2017014191A true MX2017014191A (es) 2018-08-01

Family

ID=57217933

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014191A MX2017014191A (es) 2015-05-07 2016-05-06 Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2017014192A MX2017014192A (es) 2015-05-07 2016-05-06 Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017014192A MX2017014192A (es) 2015-05-07 2016-05-06 Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.

Country Status (12)

Country Link
US (1) US20160324852A1 (es)
EP (2) EP3291815A4 (es)
JP (2) JP2018519358A (es)
KR (2) KR20180022661A (es)
CN (2) CN107949386A (es)
AU (2) AU2016258198A1 (es)
CA (2) CA2985370A1 (es)
HK (1) HK1245078A1 (es)
IL (2) IL255423A0 (es)
MX (2) MX2017014191A (es)
NO (2) NO20171941A1 (es)
WO (2) WO2016179566A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261582C1 (en) 2003-07-22 2010-01-07 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10034859B2 (en) 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US20210346374A1 (en) * 2016-10-03 2021-11-11 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 receptor antagonist
US10889635B2 (en) 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
WO2018102824A1 (en) * 2016-12-02 2018-06-07 Axovant Sciences Gmbh Methods for treating neurodegenerative disease
ES2869128T3 (es) * 2017-05-24 2021-10-25 H Lundbeck As Combinación de un antagonista de receptor 5-HT6 y un inhibidor de acetilcolinesterasa para uso en el tratamiento de la enfermedad de Alzheimer en una subpoblación de pacientes portadores de alelos ApoE4
WO2018221546A1 (en) 2017-06-01 2018-12-06 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising pde9 inhibitor
EP3628315A1 (en) * 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
RS63302B1 (sr) * 2020-05-04 2022-07-29 Bioprojet Pharma Upotreba dopaminskih d3 delimičnih agonista za tretiranje poremećaja centralnog nervnog sistema
AU2021304355A1 (en) * 2020-07-10 2023-03-02 Agenebio, Inc. Polymorphs of a GABA
CN112587534A (zh) * 2020-12-23 2021-04-02 佑嘉(杭州)生物医药科技有限公司 阿伦酸在制备治疗肝纤维化药物中的用途
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
WO2023128900A1 (en) * 2021-12-30 2023-07-06 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising pimavanserin as active ingredient and relevant excipients
WO2024040167A2 (en) * 2022-08-18 2024-02-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1497266T1 (sl) * 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
CN104739829B (zh) * 2008-10-28 2018-11-06 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
US20110251239A1 (en) * 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
US20160324852A1 (en) 2016-11-10
CN107847499A (zh) 2018-03-27
EP3291816A4 (en) 2019-01-02
AU2016258198A1 (en) 2017-11-23
MX2017014192A (es) 2018-08-01
CA2985370A1 (en) 2016-11-10
EP3291815A1 (en) 2018-03-14
AU2016256923A1 (en) 2017-11-23
EP3291816A1 (en) 2018-03-14
IL255421A0 (en) 2017-12-31
JP2018519358A (ja) 2018-07-19
CA2985366A1 (en) 2016-11-10
NO20171934A1 (en) 2017-12-05
HK1245078A1 (zh) 2018-08-24
KR20180021693A (ko) 2018-03-05
WO2016179569A1 (en) 2016-11-10
IL255423A0 (en) 2017-12-31
EP3291815A4 (en) 2019-01-16
JP2018515607A (ja) 2018-06-14
CN107949386A (zh) 2018-04-20
WO2016179566A1 (en) 2016-11-10
NO20171941A1 (en) 2017-12-05
KR20180022661A (ko) 2018-03-06

Similar Documents

Publication Publication Date Title
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
TW201713333A (en) Methods of treating a neurodegenerative disease
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
EA201691376A1 (ru) Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2021007899A (es) Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6.
NZ722600A (en) Methods of treating mild brain injury
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
IN2014CH00304A (es)
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
IN2014CH01391A (es)
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators